Daniel Heller
Partner and Chief Investment Officer @ Affinity Asset Advisors
Zürich, Switzerland
Daniel Heller is a Series A investor at Affinity Asset Advisors in Zürich focused on Therapeutics and Biotechnology. Daniel Heller currently works as the General Partner and Chief Investment Officer for Affinity Asset Advisors.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Daniel Heller invests in
Stages Daniel Heller invests in
Countries Daniel Heller invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Software 1 (33%)
- Health Care 1 (33%)
Stage
- Series A 2 (67%)
- Seed 1 (33%)
Country
- United States 2 (67%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The goal of Moodtalk is to empower employees to identify team difficulties early on, address them, and instantly implement appropriate remedies. Moodtalk's software adds structure to human dialogue, distributes solutions and inspiration, and makes behavioral changes measurable in culture transformation and strategy execution processes. | $1.1M / Seed / Jun 15, 2023 | ||
| Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS). | $75M / Series A / Jan 19, 2022 | ||
| Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy. The company is developing therapies that target cancer cells that have co-opted immune signaling pathways to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. | $15M / Series A / Jun 10, 2021 |
Co-Investors
About Affinity Asset Advisors
Affinity Asset Advisors is a healthcare-focused hedge fund with public and private investments. The company is a hedge fund manager based in New York that was founded in 2018.
Affinity Asset Advisors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Daniel Heller
Partner and Chief Investment Officer
|
|||
|
Michael Cho
Managing Partner and Portfolio Manager
|
|||
Patrick Nosker
Partner and Director of Research
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Daniel Heller invest in?
Daniel Heller invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel Heller?
Public channels for Daniel Heller include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel Heller last invest?
The most recent investment recorded for Daniel Heller closed in Jun 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
